[go: up one dir, main page]

IN2012DN03391A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03391A
IN2012DN03391A IN3391DEN2012A IN2012DN03391A IN 2012DN03391 A IN2012DN03391 A IN 2012DN03391A IN 3391DEN2012 A IN3391DEN2012 A IN 3391DEN2012A IN 2012DN03391 A IN2012DN03391 A IN 2012DN03391A
Authority
IN
India
Prior art keywords
compound
methyl
processes
relates
luoro
Prior art date
Application number
Other languages
English (en)
Inventor
David Cantin Louis
Luo Xuehong
Jerzy Tomaszewski Miroslaw
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IN2012DN03391A publication Critical patent/IN2012DN03391A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN3391DEN2012 2009-11-18 2010-11-17 IN2012DN03391A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26226309P 2009-11-18 2009-11-18
PCT/SE2010/051269 WO2011062550A1 (fr) 2009-11-18 2010-11-17 Composés de benzoimidazole et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
IN2012DN03391A true IN2012DN03391A (fr) 2015-10-23

Family

ID=44059844

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3391DEN2012 IN2012DN03391A (fr) 2009-11-18 2010-11-17

Country Status (16)

Country Link
US (1) US8530467B2 (fr)
EP (1) EP2501697B1 (fr)
JP (1) JP5657018B2 (fr)
KR (1) KR20120113709A (fr)
CN (1) CN102741245B (fr)
AR (1) AR079050A1 (fr)
AU (1) AU2010322478B2 (fr)
BR (1) BR112012011518B8 (fr)
CA (1) CA2777746C (fr)
ES (1) ES2442797T3 (fr)
IN (1) IN2012DN03391A (fr)
MX (1) MX2012005329A (fr)
RU (1) RU2542582C2 (fr)
TW (1) TW201121957A (fr)
UY (1) UY33037A (fr)
WO (1) WO2011062550A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158117A1 (fr) * 2011-05-17 2012-11-22 Astrazeneca Ab Traitements combinés pour le traitement de la douleur
WO2014117274A1 (fr) * 2013-01-31 2014-08-07 Neomed Institute Composés imidazopyridine et leurs utilisations
JP6632127B2 (ja) * 2013-12-20 2020-01-15 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物およびその中間体の製造方法
EP3981406A1 (fr) * 2014-07-03 2022-04-13 Afferent Pharmaceuticals Inc. Procédés et compositions pour traiter les maladies et les affections
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (zh) * 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用
SG11202106706TA (en) * 2018-12-29 2021-07-29 Wuhan Ll Science And Technology Development Co Ltd Heterocyclic compound intermediate, preparation method therefor and application thereof
CN113727716A (zh) 2019-02-25 2021-11-30 贝卢斯医疗咳嗽病公司 采用p2x3调节剂的治疗
WO2021161105A1 (fr) * 2020-02-14 2021-08-19 Bellus Health Cough Inc. Modulateurs de p2x3
WO2022033567A1 (fr) * 2020-08-13 2022-02-17 上海拓界生物医药科技有限公司 Dérivés de benzimidazole, leur procédé de préparation et leur utilisation médicale
WO2022117062A1 (fr) * 2020-12-04 2022-06-09 上海拓界生物医药科技有限公司 Composés contenant un noyau tricyclique condensé et leur utilisation pharmaceutique
CN114478508A (zh) * 2021-12-31 2022-05-13 淮北师范大学 一种苯并咪唑化合物的结晶形式
WO2023151658A1 (fr) * 2022-02-11 2023-08-17 江苏恒瑞医药股份有限公司 Sel pharmaceutiquement acceptable d'un antagoniste du récepteur p2x3 et son procédé de préparation
CN118556054A (zh) * 2022-02-11 2024-08-27 江苏恒瑞医药股份有限公司 一种p2x3受体拮抗剂的结晶形式及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6026A (en) * 1849-01-09 Cast-iron car-wheel
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (fr) 1996-02-13 1997-08-21 Zeneca Limited Derives de la quinazoline utilises comme inhibiteurs du vegf
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
JP4059671B2 (ja) * 2000-01-17 2008-03-12 帝人株式会社 ベンズイミダゾール誘導体
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
BR0112225A (pt) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto
BRPI0515897A (pt) * 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
AR065495A1 (es) * 2007-03-02 2009-06-10 Schering Corp Metodos para usar derivados de bencimidazol para tratar o prevenir dolor, diabetes, complicacion diabetica composiciones.
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
JP2011502148A (ja) * 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛の治療用としてのp2x3受容体アンタゴニスト

Also Published As

Publication number Publication date
WO2011062550A1 (fr) 2011-05-26
US8530467B2 (en) 2013-09-10
ES2442797T3 (es) 2014-02-13
AR079050A1 (es) 2011-12-21
JP2013511517A (ja) 2013-04-04
BR112012011518B8 (pt) 2023-01-10
MX2012005329A (es) 2012-05-29
CA2777746C (fr) 2019-05-14
AU2010322478B2 (en) 2013-11-14
EP2501697A4 (fr) 2013-04-24
RU2542582C2 (ru) 2015-02-20
KR20120113709A (ko) 2012-10-15
CN102741245A (zh) 2012-10-17
US20120289504A1 (en) 2012-11-15
EP2501697B1 (fr) 2013-10-23
AU2010322478A1 (en) 2012-05-31
TW201121957A (en) 2011-07-01
CA2777746A1 (fr) 2011-05-26
JP5657018B2 (ja) 2015-01-21
RU2012124268A (ru) 2013-12-27
UY33037A (es) 2011-06-30
CN102741245B (zh) 2014-11-05
BR112012011518A2 (pt) 2016-06-28
BR112012011518B1 (pt) 2020-03-10
EP2501697A1 (fr) 2012-09-26

Similar Documents

Publication Publication Date Title
IN2012DN03391A (fr)
TN2012000347A1 (en) 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UA106199C2 (ru) Производные аминобензамида как агенты, пригодные для использования для борьбы с паразитами животных
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
JO2962B1 (en) Aminopronic derivatives substituted as niprilicin inhibitors
UA102179C2 (xx) Фунгіцидна композиція$фунгицидная композиция
UA101819C2 (en) Herbicidal 1h-2-thia-1,5,8-triazanaphthalene-2,2-dioxides
NZ592382A (en) Thioamide compounds, method of making and method of using thereof
BR112012009214A2 (pt) compostos
NZ593874A (en) Nalmefene hydrochloride dihydrate
IN2012DN01298A (fr)
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
MY151229A (en) Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
WO2011159124A3 (fr) Nouveau dérivé de benzoxazole présentant une activité inhibitrice contre l'interleukine 6, procédé pour le préparer, et composition pharmaceutique le contenant
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
WO2010056644A8 (fr) 1-(arylsulfonyl)-4-(pipérazin-1-yl)-1h-benzimidazoles en tant que ligands de δ-hydroxytriptamine-6
BR112012012755A2 (pt) "composto de fórmula (i), composição fungicida e método para controle do fungo fitopatogênico de culturas"
UA107831C2 (en) Composition for combating plant diseases and its application
UA105022C2 (uk) Композиція для боротьби з хворобами рослин та спосіб боротьби з хворобами рослин
WO2009145591A3 (fr) Composés de phényl-pipérazine, composition pharmaceutique les comprenant, et utilisation associée
MY173914A (en) Pesticidal composition and method for controlling pests
UA110577C2 (uk) Агент для боротьби з захворюваннями рослин, спосіб боротьби з захворюваннями рослин і продукт для боротьби з захворюваннями
IN2014DN06122A (fr)